| __timestamp | BeiGene, Ltd. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 14400000 |
| Thursday, January 1, 2015 | 58250000 | 33800000 |
| Friday, January 1, 2016 | 98033000 | 35900000 |
| Sunday, January 1, 2017 | 273992000 | 1254000 |
| Monday, January 1, 2018 | 707710000 | 4889000 |
| Tuesday, January 1, 2019 | 998528000 | 7400000 |
| Wednesday, January 1, 2020 | 1365534000 | 10100000 |
| Friday, January 1, 2021 | 1624145000 | 14300000 |
| Saturday, January 1, 2022 | 1926983000 | 23200000 |
| Sunday, January 1, 2023 | 379920000 | 39700000 |
| Monday, January 1, 2024 | 34000000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, understanding cost structures is pivotal. This analysis delves into the cost of revenue trends for BeiGene, Ltd. and Neurocrine Biosciences, Inc. from 2014 to 2023. Over this period, BeiGene's cost of revenue surged by an astounding 8,700%, peaking in 2022, reflecting its aggressive expansion and investment in research and development. In contrast, Neurocrine Biosciences exhibited a more modest growth of 175%, with a notable spike in 2023, indicating strategic scaling.
The data reveals BeiGene's commitment to innovation, as evidenced by its substantial cost increases, while Neurocrine's steady rise suggests a more measured approach. These insights offer a glimpse into the strategic priorities of these biotech giants, highlighting the diverse paths companies take in the pursuit of scientific breakthroughs.
Cost Insights: Breaking Down Novo Nordisk A/S and BeiGene, Ltd.'s Expenses
Cost of Revenue Trends: Sanofi vs BeiGene, Ltd.
Cost of Revenue Trends: Bristol-Myers Squibb Company vs BeiGene, Ltd.
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
BeiGene, Ltd. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down BeiGene, Ltd. and Dyne Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: United Therapeutics Corporation and Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and Incyte Corporation
Cost Insights: Breaking Down Neurocrine Biosciences, Inc. and Dr. Reddy's Laboratories Limited's Expenses
Cost of Revenue: Key Insights for Neurocrine Biosciences, Inc. and ADMA Biologics, Inc.
Analyzing Cost of Revenue: Neurocrine Biosciences, Inc. and Travere Therapeutics, Inc.
Neurocrine Biosciences, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored